Comparing SG&A Expenses: ACADIA Pharmaceuticals Inc. vs Viridian Therapeutics, Inc. Trends and Insights

Biotech Giants: SG&A Expense Trends Over a Decade

__timestampACADIA Pharmaceuticals Inc.Viridian Therapeutics, Inc.
Wednesday, January 1, 2014327480007751000
Thursday, January 1, 20159080400010251000
Friday, January 1, 20161864560009575000
Sunday, January 1, 201725506200010912000
Monday, January 1, 201826575800011049000
Tuesday, January 1, 201932563800011646000
Wednesday, January 1, 202038866100013265000
Friday, January 1, 202139602800025805000
Saturday, January 1, 202236909000035182000
Sunday, January 1, 202340246600094999000
Loading chart...

Unlocking the unknown

SG&A Expenses: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of ACADIA Pharmaceuticals Inc. and Viridian Therapeutics, Inc. over the past decade. From 2014 to 2023, ACADIA's SG&A expenses surged by over 1,100%, reflecting its aggressive growth strategy. In contrast, Viridian's expenses increased by approximately 1,200%, albeit from a much smaller base, indicating its rapid expansion phase.

Key Insights

  • ACADIA Pharmaceuticals Inc.: Starting with a modest $32.7 million in 2014, ACADIA's expenses peaked at $402.5 million in 2023, showcasing its commitment to scaling operations.
  • Viridian Therapeutics, Inc.: Despite starting with just $7.8 million in 2014, Viridian's expenses reached $94.9 million by 2023, highlighting its dynamic growth trajectory.

This comparison underscores the diverse strategies employed by biotech firms in managing their operational expenditures.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025